文献速递消化系统肿瘤

A140联合mFOLFOX6对比西妥昔单抗联合mFOLFOX6一线治疗RAS野生型转移性结直肠癌:一项随机临床试验

A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
PubMed 文献 · Eur J Cancer · 2025-06-07

这项在中国开展的3期随机双盲多中心等效性试验纳入688例RAS野生型转移性结直肠癌患者,1:1随机接受A140或西妥昔单抗联合mFOLFOX6治疗≤16周。16周内A140组ORR为71.0%,西妥昔单抗组为77.5%,ORR比值为0.93(90%CI 0.87-0.99),落在预设等效区间0.83-1.20内。中位随访19.6个月,两组PFS、OS、缓解持续时间及安全性、免疫原性相似,未见新安全信号。

要点

  • 16周内ORR:A140组71.0% vs 西妥昔单抗组77.5%,ORR比值0.93(90%CI 0.87-0.99),在0.83-1.20等效区间内。
  • 中位随访19.6个月,两组PFS、OS、缓解持续时间未见明显差异。
  • 两组安全性和免疫原性相似,未观察到新的安全信号。

核心结论

  • A140联合mFOLFOX6与西妥昔单抗联合mFOLFOX6治疗RAS野生型转移性结直肠癌等效,安全性无显著差异。
  • 作者认为A140联合mFOLFOX6可能为RAS野生型转移性结直肠癌患者提供新的治疗选择。

研究设计与样本

  • 3期随机双盲多中心等效性试验,在中国开展,试验注册号NCT04835142。
  • 纳入18-75岁、组织学确诊的RAS野生型转移性结直肠癌、ECOG评分0-1的患者,1:1随机接受A140(n=341)或西妥昔单抗(n=347)联合mFOLFOX6治疗≤16周,直至疾病进展或不可耐受毒性。
  • 16周治疗期后,研究者认为可获益的患者接受A140联合mFOLFOX6治疗。
  • 主要终点为16周内由独立评审委员会按RECIST v1.1评估的客观缓解率(ORR);若ORR比值的90%CI在0.83-1.20之间则认为A140等效。
  • 次要终点包括无进展生存期(PFS)、总生存期(OS)、安全性、免疫原性和药代动力学。

主要发现

  • 截至2023年3月22日,ORR为A140组71.0% vs 西妥昔单抗组77.5%,ORR比值为0.93(90%CI 0.87-0.99)。
  • 中位随访19.6个月,两组PFS、OS和缓解持续时间未见明显差异。
  • 两组安全性和免疫原性相似,未观察到新的安全信号。

关键数值与推荐

  • 等效性判定标准:ORR比值的90%CI在0.83-1.20之间则认为A140等效,实际ORR比值0.93(90%CI 0.87-0.99)。

临床怎么用

  • 作者认为A140联合mFOLFOX6可能为RAS野生型转移性结直肠癌患者提供新的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: EGFR inhibition, combined with chemotherapy, forms a mainstay of treatment of first-line RAS wild-type (RASwt) metastatic CRC (mCRC). We compared the anti-EGFR antibody, A140, with cetuximab (both combined with chemotherapy) for RASwt mCRC. METHODS: In this phase 3, randomized, double-blind, multi-center equivalence trial in China, patients were randomized (1:1) to oxaliplatin, 5-fluorouracil, and leucovorin (modified [m] FOLFOX6), plus either A140 or cetuximab for ≤ 16 weeks until disease progression or unacceptable toxicity. After the 16-week treatment period, patients who investigators deemed could benefit received A140 plus mFOLFOX6. Eligible patients were 18-75 years old with histologically confirmed RASwt mCRC and an Eastern Cooperative Oncology Group (ECOG) score of 0-1. Primary endpoint was objective response rate (ORR [RECIST v1.1]), per independent review committee, over the 16 weeks. A140 was considered equivalent if the 90 % CIs for the ORR ratio were between 0.83 and 1.20. Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, immunogenicity, and pharmacokinetics. RESULTS: Overall, 688 patients were randomized to A140 (n = 341) or cetuximab (n = 347). As of 22-Mar-2023, the ORR was 71.0 % (A140) and 77.5 % (cetuximab); the ORR ratio was 0.93 (90 % CI, 0.87-0.99). With a median follow-up of 19.6 months, no notable differences in PFS, OS, or duration of response were observed between arms. Safety profiles and immunogenicity were similar between arms and no new safety signals were observed. CONCLUSION: A140 plus mFOLFOX6 is equivalent to cetuximab plus mFOLFOX6 for RASwt mCRC, with no appreciable differences in safety profiles. A140 plus mFOLFOX6 may provide a new treatment option for patients with RASwt mCRC. TRIAL REGISTRATION: NCT04835142.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Liu R, Yin X, Bai Y, et al. A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial. Eur J Cancer. 2025. PMID: 40737898. doi:10.1016/j.ejca.2025.115566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。